Burning Rock Biotech Limited (BNR) Tops Q1 EPS by 13c; Offers Guidance

Burning Rock Biotech Limited (NASDAQ: BNR) reported Q1 EPS of (RMB1.81), RMB0.13 better than the analyst estimate of (RMB1.94). Revenue for the quarter came in at RMB142.52 million versus the consensus estimate of RMB143 million.

2023 Financial Guidance

We reiterate our 2023 full-year revenue guidance of approximately 20% growth over 2022 vs. estimated growth of 20.1% Y/Y.

For earnings history and earnings-related data on Burning Rock Biotech Limited (BNR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c